EcoDrugPlus

Calcium Channel, Voltage-Dependent, T Type, Alpha 1h Subunit

Ensembl ID : ENSXETG00000022646
Gene Symbol: CACNA1H
2 Enzyme and pathways 5 View Cross-references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, T Type, Alpha 1i Subunit

Ensembl ID : ENSXETG00000016133
Gene Symbol: CACNA1I
2 Enzyme and pathways 5 View Cross-references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1

Ensembl ID : ENSXETG00000007868
Gene Symbol: CACNA2D1
5 View Cross-references
294 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 3

Ensembl ID : ENSXETG00000036769
Gene Symbol: CACNA2D3
3 Enzyme and pathways 5 View Cross-references
310 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 4

Ensembl ID : ENSXETG00000000900
Gene Symbol: CACNA2D4
5 View Cross-references
318 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSXETG00000026334
Gene Symbol: CACNB1
7 Enzyme and pathways 5 View Cross-references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Beta 2 Subunit

Ensembl ID : ENSXETG00000022755
Gene Symbol: CACNB2
10 Enzyme and pathways 5 View Cross-references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Beta 3 Subunit

Ensembl ID : ENSXETG00000041393
Gene Symbol: CACNB3
6 Enzyme and pathways 5 View Cross-references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Beta 4 Subunit

Ensembl ID : ENSXETG00000021694
Gene Symbol: CACNB4
3 Enzyme and pathways 5 View Cross-references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Gamma Subunit 1

Ensembl ID : ENSXETG00000037972
Gene Symbol: CACNG1
5 View Cross-references
509 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Gamma Subunit 2

Ensembl ID : ENSXETG00000031321
Gene Symbol: CACNG2
3 Enzyme and pathways 5 View Cross-references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, Gamma Subunit 3

Ensembl ID : ENSXETG00000040408
Gene Symbol: CACNG3
5 View Cross-references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).